Project Details
Description
Open-label, randomized, assessor-blinded, efficacy, safety, tolerability, and pharmacokinetics study of subcutaneous risankizumab with an adalimumab reference arm in children with active juvenile psoriatic arthritis (Study M23-732)
| Status | Active |
|---|---|
| Effective start/end date | 10/11/23 → 10/31/33 |
Funding
- ABBVIE INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.